Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | EGFR | P00533 | 1/20 | 0.65 |
| ▸ | LCK | P06239 | 1/20 | 0.65 |
| ▸ | FYN | P06241 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.64 |
| ▸ | GRM8 | O00222 | 3/20 | 0.53 |
| ▸ | GRM6 | O15303 | 3/20 | 0.53 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4502044 | 1.00 | SLC7A5 (0.65) | SLC7A5ALOX15HSD17B10PTGS1KDM4E | |
| SCHEMBL28040458 | 1.00 | SLC7A5 (0.65) | SLC7A5ALOX15HSD17B10PTGS1KDM4E | |
| SCHEMBL38175 | 1.00 | SLC7A5 (0.65) | SLC7A5ALOX15HSD17B10PTGS1KDM4E | |
| SCHEMBL28040459 | 1.00 | SLC7A5 (0.65) | SLC7A5ALOX15HSD17B10PTGS1KDM4E | |
| SCHEMBL108202 | 1.00 | SLC7A5 (0.65) | SLC7A5ALOX15HSD17B10PTGS1KDM4E | |
| Tetranitromethane SCHEMBL27519009 | 0.93 | GRM4 (0.58) | SLC7A5ALOX15HSD17B10PTGS1KDM4E | |
| Phenol SCHEMBL29144981 | 0.93 | GRM4 (0.58) | SLC7A5ALOX15HSD17B10PTGS1KDM4E | |
| SCHEMBL16915278 | 0.92 | GRM4 (0.57) | SLC7A5ALOX15HSD17B10PTGS1KDM4E | |
| SCHEMBL16915277 | 0.92 | GRM4 (0.57) | SLC7A5ALOX15HSD17B10PTGS1KDM4E | |
| Norleucine SCHEMBL27238061 | 0.89 | GRM4 (0.59) | SLC7A5ALOX15HSD17B10PTGS1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098058-A1 | COMPOUND - DIAGNOSTIC MARKER FOR OVARIAN CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF OVARIAN CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF OVARIAN CANCER | URTESTE S.A. (PL) | 2026-04-09 | — | — | US | claimed |
| US-12521455-B2 | Kisspeptin receptor (KISS1R) targeted therapeutics and uses thereof | RADIONETICS ONCOLOGY, INC. (US) | 2026-01-13 | — | — | US | claimed |
| US-20250376711-A1 | COMPOUND-DIAGNOSTIC MARKER FOR UTERINE BODY CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF UTERINE BODY CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF UTERINE BODY CANCER | URTESTE S.A. (PL) | 2025-12-11 | — | — | US | claimed |
| EP-4649167-A2 | COMPOUND - DIAGNOSTIC MARKER FOR BILIARY TRACT CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF BILIARY TRACT CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF BILIARY TRACT CANCER | Urteste S.A. (PL) | 2025-11-19 | — | — | EP | claimed |
| WO-2025216642-A1 | ENZYMATIC ACTIVITY BASED METHOD AND MARKER FOR THE DIAGNOSIS OF BRAIN TUMOUR | URTESTE S.A. (PL) | 2025-10-16 | — | — | WO | claimed |
| US-20250312499-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2025-10-09 | — | — | US | claimed |
| US-20250270617-A1 | Compound - diagnostic marker for kidney cancer, method for detecting enzymatic activity, method for diagnosis of kidney cancer, kit comprising the compound, uses of the compound and method for the treatment of kidney cancer | URTESTE S.A. (PL) | 2025-08-28 | — | — | US | claimed |
| EP-3788149-B1 | A METHOD FOR OPTIMIZING ANTIBODY EXPRESSION | AMBRX INC (US) | 2025-08-27 | — | — | EP | claimed |
| EP-4594335-A1 | COMPOUND - DIAGNOSTIC MARKER FOR OVARIAN CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF OVARIAN CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF OVARIAN CANCER | Urteste S.A. (PL) | 2025-08-06 | — | — | EP | claimed |
| US-20250206777-A1 | COMPOUND - DIAGNOSTIC MARKER FOR INTESTINAL CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF INTESTINAL CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF INTESTINAL CANCER | URTESTE S.A. (PL) | 2025-06-26 | — | — | US | claimed |
| EP-3630977-B1 | METHODS AND COMPOSITIONS FOR PROMOTING NON-NATURAL AMINO ACID-CONTAINING PROTEIN PRODUCTION | AMBRX INC (US) | 2024-02-21 | — | — | EP | claimed |
| WO-2024005658-A1 | COMPOUND-DIAGNOSTIC MARKER FOR UTERINE BODY CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF UTERINE BODY CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF UTERINE BODY CANCER | URTESTE S.A. (PL) | 2024-01-04 | — | — | WO | claimed |
| WO-2023191647-A1 | COMPOUND - DIAGNOSTIC MARKER FOR INTESTINAL CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF INTESTINAL CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF INTESTINAL CANCER | URTESTE S.A. (PL) | 2023-10-05 | — | — | WO | claimed |
| US-20230204587-A1 | NOVEL DIAGNOSTIC MARKER FOR PROSTATE CANCER | URTESTE S.A. (PL) | 2023-06-29 | — | — | US | claimed |
| WO-2023080800-A1 | FRET ENZYMATIC SUBSTRATE AND USES THEREOF IN LIVER CANCER. | URTESTE S.A. (PL) | 2023-05-11 | — | — | WO | claimed |
| CN-115989413-A | Novel diagnostic marker for prostate cancer | 尔特斯特公司 | 2023-04-18 | — | — | CN | claimed |
| WO-2022248061-A1 | MICROORGANISMS AND USES THEREOF | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2022-12-01 | — | — | WO | claimed |
| CN-114096555-A | Novel pancreatic cancer diagnostic marker | 尔特斯特公司 | 2022-02-25 | — | — | CN | claimed |
| WO-2011048080-A1 | 3-NITROTYROSINATED FIBRINOGEN AS A DIAGNOSTIC MARKER IN ISCHEMIC STROKE AND USES THEREOF | UNIVERSITAT POMPEU FABRA (ES) | 2011-04-28 | — | — | WO | claimed |
| EP-2315032-A1 | 3-Nitrotyrosinated fibrinogen as a diagnostic marker in ischemic stroke and uses thereof | Universitat Pompeu-Fabra (ES) | 2011-04-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312499-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | KISS1R, GNRHR, PROKR1 | SLC7A5 2164/4885ALOX15 4665/4885HSD17B10 3643/4885 |
| US-20260098058-A1 | COMPOUND - DIAGNOSTIC MARKER FOR OVARIAN CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF OVARIAN CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF OVARIAN CANCER | DNPEP, ANPEP, CA9 | SLC7A5 1094/4885ALOX15 640/4885HSD17B10 2430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.